Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib

The Bruton tyrosine kinase (BTK) inhibitor ibrutinib has excellent clinical activity in patients with chronic lymphocytic leukemia (CLL). Characteristically, ibrutinib causes CLL cell redistribution from tissue sites into the peripheral blood during the initial weeks of therapy. To better characteri...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Wodarz, Dominik, Garg, Naveen, Komarova, Natalia L., Benjamini, Ohad, Keating, Michael J., Wierda, William G., Kantarjian, Hagop, James, Danelle, O’Brien, Susan, Burger, Jan A.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2014
Matèries:
Lymphoid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4123432/
https://ncbi.nlm.nih.gov/pubmed/24829205
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-02-554220
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars